Full Interview Summary: Venture capitalists evaluating the addiction treatment spaceparticularly those exploring GLP-1 drugs and psychedelicsface significant regulatory and legal hurdles
March 31st, 2025: Plaintiffs Push Back on Ozempic Dismissal Motion, Accuse Drug Makers of Downplaying GI Risks Plaintiffs in the GLP-1 drug litigationincluding claims involving Ozempic, Wegovy, and Mounjarohave asked a federal judge to reject dismissal efforts by Novo Nordisk and Eli Lilly
Treatment decisions often depend on: The best option is the one that aligns with a patients health profile and can be followed consistently over time
Combined use : Very few studies have directly assessed inositol and berberine together
When medication and lifestyle work together, patients often experience steady, sustainable progress
While the exact connection between AD and T2DM remains unclear, insulin resistance contributes to cognitive decline